Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-Meso: Volrustomig in Unresectable Pleural Mesothelioma
NCT06097728Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Nov 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of volrustomig in pleural mesothelioma, sponsored by AstraZeneca. Started Nov 2023; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NCT06097728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097728.